Evidence map›Paper›PMID 22633904›Full record

ArticleInternational journal of pharmaceutics2012

RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Rajendra S Kadam, Puneet Tyagi, Henry F Edelhauser, Uday B Kompella

RetractedAbstract readComparative Study
In one paragraph

Article in International journal of pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Nanotechnology approaches for ocular drug delivery.Middle East African journal of ophthalmology
    Review
4 · The record

Corrections and comments

  • Retraction · 2015-01-01Falsification/Fabrication of Data · Falsification/Fabrication of Results · Miscommunication with/by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · · exact date of retraction unknown; Rajendra Kadam named responsible for misconduct
  • Commented on by
5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rajendra S KadamDepartments of Pharmaceutical Sciences and Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Puneet Tyagi
Henry F Edelhauser
Uday B Kompella
University of Colorado Anschutz Medical Campus · USEmory Eye Center · US

Funding

Transscleral Drug Delivery for Retinal DisordersR24EY017045 · NEI · EMORY UNIVERSITY · PI EDELHAUSER, HENRY FRANCIS · 2006 to 2010
$6.9M
Transcleral Therapeutics in Diabetic RetinopathyR01EY018940 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2010 to 2014
$2.4M
Influence of eye pigmentation and diabetes on retinal drug deliveryR01EY017533 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2009 to 2010
$806k
NEI NIH HHS EY017045NEI NIH HHS EY017533NEI NIH HHS EY018940NEI NIH HHS R01 EY017533NEI NIH HHS R01 EY018940NEI NIH HHS R24 EY017045
6 · The paper itself

Abstract

purposeOne objective of this study was to determine whether polymeric nanoparticles and/or microparticles sustain transscleral choroidal and retinal delivery of triamcinolone acetonide (TA) for two months in therapeutically effective concentrations after single periocular administration. Another objective of this study was to assess the influence of choroidal neovascularization on transscleral delivery of TA.

methodsPolymeric nano- and micro-particles of TA were prepared by o/w emulsion-solvent evaporation method using poly-l-lactide (PLA). Particles were characterized for drug loading, size, surface morphology, and the in vitro drug release profile. Choroidal neovascularization (CNV) was induced in brown Norway (BN) rats using a 532 nm diode argon laser and the CNV induction was assessed using fluorescein angiography. In vivo delivery was assessed in control and CNV induced rats at 2 months after periocular injection of TA loaded nano- or micro-particle suspension, or plain TA suspension in PBS (pH 7.4). Ocular tissue levels of TA were estimated using LC-MS/MS following liquid-liquid extraction of drug from tissue samples. Nile red loaded microparticles entrapped in periocular tissue at the end of the study was visualized using scanning electron microscopy and confocal microscopy. Inhibitory effect of TA on VEGF secretion was evaluated in ARPE-19 cells.

resultsTriamcinolone acetonide-PLA nano- (551 nm) and micro-particles (2090 nm), with 14.7 and 29.5% drug loading, respectively, sustained in vitro TA release for about 45 and 120 days. After subconjunctival injection, microparticles were able to sustain the delivery in all intraocular tissues for 2 months; whereas no drug levels were detected for TA loaded nanoparticles and plain suspension of TA. Intraocular delivery of TA from microparticles was higher in CNV induced rats when compared to control rats. Significant amount of microparticles remained in periocular tissue at 2 months after injection, and maintained spherical shape. TA decreased VEGF secretion by 50% at 0.07 μM. At the end of the in vivo study, choroid-RPE and retina TA levels in CNV induced rats were 16- and 5-fold higher than the IC(50) for VEGF secretion.

conclusionsSingle periocular injection of polymeric microparticles but not nanoparticles sustained effective levels of TA in choroid-RPE and retina for 2 months, with the TA delivery being greater in CNV induced rats than the control rats.

Indexed as

Drug Delivery SystemsAdministration, OphthalmicAnimalsCell LineChoroidal NeovascularizationDelayed-Action PreparationsDrug CarriersEmulsionsGlucocorticoidsHumansInhibitory Concentration 50MaleMicrospheresNanoparticlesParticle SizePolyestersDelayed-Action PreparationsDrug CarriersEmulsionsGlucocorticoidsPolyesterspoly(lactide)Triamcinolone AcetonideVascular Endothelial Growth Factor A

Identifiers

PMID22633904
PMCPMC3573139
OpenAlexW2016877956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.